RADIOTHERAPY
JUST Leveled Up



Watch video

 

Turning cancer on
itself > Finally

SCINTIX therapy detects and responds to signals emitted from the cancer itself and, for the first time, uses them to deliver immediate treatment for tumors in the lung or bone that may arise from primary or metastatic disease.

SELF-DRIVING RADIOTHERAPY

Cancer is talking.
We’re listening.

When radiopharmaceuticals are introduced into the body, cancer cells absorb them and create a biological beacon, which our machine uses to manage motion and treat solid tumors of any stage disease.

Learn About Emissions

Targeting Cancer

GOOD NEWS FOR ORGANS.
BAD NEWS FOR TUMORS.

Our SCINTIX technology delivers high doses of radiation to tumors, even those in motion. Live targeting allows for greater impact to the tumor and potentially less dose to surrounding tissues.

Learn About Targeting

ANY STAGE TUMOR

A world where stage
is just a number.

Most patients with stage four cancer are not considered candidates for definitive radiotherapy. Our breakthrough SCINTIX therapy creates a new option for patients with lung or bone tumors arising from primary or metastatic cancer.

Discover the Potential

Combination Treatment

Come at cancer
from every angle.

Treatment isn’t a one-size-fits-all situation. For many patients, the best treatment plan is a combination of multiple therapies. Adding SCINTIX therapy to chemotherapy, immunotherapy and targeted drugs may potentially improve outcomes.

Learn About Treatment

Learn more about our breakthrough technology

SCINTIX Biology-guided Radiotherapy

By combining PET-CT and radiotherapy, we're able to find and treat cancer using emissions created by tumors themselves.

Clinicians

Discover SCINTIX therapy.

Cancer Centers

See how SCINTIX therapy can play a role
in your cancer program.

Make every day count

See Available Positions

Latest

Press Releases

RefleXion Receives FDA Clearance for SCINTIX Biology-Guided Radiotherapy; Cutting-edge Treatment Applicable for Early and Late-stage Cancers  

 Each cancer’s unique biology provides second-by-second information to direct radiotherapy  Company to host live stream YouTube event today at 10:30 AM PST HAYWARD, Calif., Feb. 2, 2023 – RefleXion Medical, a therapeutic oncology company, today announced the U.S. Food and Drug Administration (FDA) has granted the first marketing clearance for its SCINTIX™ biology-guided radiotherapy, a […]

View All Press chevron right

News

Fresh $80M Round Aims to Help East Bay Company Zap Cancer

Sam Mazin wandered into a lecture at Stanford University 15 years ago, and today his company said it walked away with $80 million for a machine aimed at zapping tough-to-treat, late-stage cancers.

View All News chevron right

Blog

RefleXion Highlights at ASTRO 2022: SCINTIX Therapy, Science and Sharing

Booth #3745 in the exhibit hall at ASTRO’s annual conference in San Antonio, Texas, was bustling with activity. Thousands of radiation oncologists convene at ASTRO each year to learn and share advances in radiotherapy planning and treatment. Conference attendees stopped by to ask questions and watch demonstrations of RefleXion Medical’s X1 platform. For the first […]

View All Blog Posts chevron right

Feedback
and
Inquiries.

Let us tell you more.

Contact Us

Sign up for our
latest news and information.

Stay up to date.

Sign Up